
==== Front
Sao Paulo Med J
Sao Paulo Med J
Sao Paulo Med J
São Paulo Medical Journal
1516-3180
1806-9460
Associação Paulista de Medicina - APM

12920477
10.1590/S1516-31802003000300010
Review Article
Beckwith-Wiedemann syndrome and isolated hemihyperplasia
de Matos Gomes Marcus Vinícius *
Ramos Ester Silveira *
Address for correspondence Marcus Vinícius de Matos Gomes Departamento de Genética da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo Avenida Bandeirantes, 3900 – Bloco C Ribeirão Preto/SP – Brasil – CEP 14049-900 Tel: (+55 16) 602-3076/602-3164 E-mail: mvmgomes@rge.fmrp.usp.br
Conflicts of interest: Not declared

01 5 2003
2003
121 3 133138
28 11 2002
13 12 2002
17 2 2003
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons license.
ABSTRACT

CONTEXT:

Beckwith-Wiedemann syndrome is a complex and heterogeneous overgrowth syndrome with genetic and epigenetic alterations, involving genomic imprinting and cancer predisposition. Isolated hemihyperplasia is of unknown cause, and it may represent a partial or incomplete expression of Beckwith-Wiedemann syndrome.

OBJECTIVES:

A clinical and molecular review and proposal of the use of an experimental protocol to provide a practical approach for the physician.

DATA SYNTHESIS:

This review demonstrates the genetic and epigenetic mechanisms involved in the Beckwith-Wiedemann syndrome and isolated hemihyperplasia, and the candidate genes. To our knowledge, this is the first Brazilian protocol for research into these disorders. The results have been used at the Faculdade de Medicina de Ribeir ão Preto, Universidade de São Paulo, to elucidate the basis of Beckwith-Wiedemann syndrome and isolated hemihyperplasia, and have been applied at the Hospital Universitário of the Faculdade de Medicina.

CONCLUSIONS:

Elucidation of the etiological mechanisms and use of a laboratory protocol to detect alterations in these disorders may be useful for guiding the management of such patients and genetic counseling of the families.

RESUMO

CONTEXTO:

A síndrome de Beckwith-Wiedemann é uma doença de hipercrescimento complexa e heterogênea com alterações genéticas e epigenéticas, envolvendo imprinting genômico e predisposição ao câncer. A causa da hemi-hiperplasia isolada ainda é desconhecida e pode representar uma expressão parcial ou incompleta da síndrome de Beckwith-Wiedemann.

OBJETIVOS:

Revisão clínica e molecular e proposta de um protocolo experimental para utilização na prática médica.

SÍNTESE DOS DADOS:

Esta revisão apresenta os mecanismos genéticos e epigenéticos envolvidos na síndrome de Beckwith-Wiedemann e na hemi-hiperplasia isolada, os genes candidatos e o primeiro protocolo brasileiro, de que temos conhecimento, para a pesquisa dessas doenças. Os resultados têm sido utilizados na Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para elucidar as bases da síndrome de Beckwith-Wiedemann/hemi-hiperplasia isolada e aplicados no Hospital das Clínicas desta Faculdade.

CONCLUSÕES:

A elucidação dos mecanismos etiológicos e o uso de um protocolo laboratorial para se detectar as alterações nessas doenças pode ser proveitoso no acompanhamento clínico dos pacientes e no aconselhamento genético das famílias.

KEY WORDS:

Beckwith-Wiedemann syndrome
Imprinting
Methylation
Isolated hemihyperplasia
Cancer
PALAVRAS CHAVE:

Síndrome de Beckwith-Wiedemann
Imprinting
Metilação
Hemihiperplasia isolada
Câncer
==== Body
pmcINTRODUCTION

Beckwith-Wiedemann syndrome

Beckwith-Wiedemann syndrome is a congenital disorder first recognized in 1964 by Dr. H.R. Wiedemann,1 a geneticist, and then in 1969 by Dr. J. Bruce Beckwith,2 a pediatric pathologist. The syndrome is usually sporadic, but may be inherited.3 The incidence has been report to be approximately 1:13,700 births.4

The most common phenotypes associated are:

Macroglossia: larger than usual for an infant, may disturb the child's ability to eat, breathe or speak. In severe cases, corrective surgery may be necessary. The enlargement is no longer apparent by 6-8 years of age.

Abdominal wall defects (omphalocele, umbilical hernia, diastasis recti).

Increased growth: birth weight and length (usually above the mean), visceromegaly (particularly kidneys, liver, and pancreas) and hemihyperplasia (usually all or part of one side of the body).

Ear lobe creases, first described by Irving (1967) and then used as one of the criteria for diagnosis of the illness, and/or pit indentations on the posterior helix.5-8

Macroglossia, together with omphalocele or other umbilical abnormalities, allows recognition of the disorder at birth. Sometimes hemihyperplasia is not present at birth but becomes apparent later in childhood. It can be noted in approximately 12.5% of the cases and is present in 40% of the children who develop tumors (Figure 1).9

Figure 1 Common phenotypes associated with Beckwith-Wiedemann syndrome: A) macroglossia and facial/tongue hemihyperplasia, B) ear lobe creases, C) pit on posterior helix.

The risk situations are:

Hypoglycemia, which occurs shortly after birth. Although it is usually temporary, if untreated, it can cause seizures and hypoxia, leading to severe complications, including mental deficiency.10

Premature birth and its complications.

Development of tumors: children with Beckwith-Wiedemann syndrome have a 7-21% risk for the development of embryonic malignancies, most notably Wilms’ umor of the kidney,11-13 although a wide variety of benign and malignant tumors have been reported, including hepatoblastoma, adrenocortical carcinoma, rhabdomyosarcoma and neuroblastoma.8,13

Isolated hemihyperplasia

Hemihyperplasia is clinically defined as asymmetric overgrowth of one or more body parts. The overgrowth may involve an entire half of the body, a single limb, and/or one side of the face or combinations thereof. There may be accompanying asymmetric visceromegaly.14

It may be an isolated finding, or it may be associated with a variety of multiple malformation syndromes. Rowe et al (1962)15 proposed a classification system for hemihyperplasia, based on anatomic site of involvement: a) complex hemihyperplasia – involvement of half of the body (at least one arm and one leg), in which the affected parts may be contra or ipsilateral; b) simple hemihyperplasia – involvement of a single limb; c) hemifacial hyperplasia – involvement of one side of the face. The incidence of isolated hemihyperplasia has been report to be approximately 1:86,000 live births16,17 and increased birth weight has been observed (mean of 3.8 kg).18 Hoyme et al (1998)17 reported an increase in the incidence of certain abdominal tumors in children with isolated hemihyperplasia (5.9%), in comparison with the general population.

Genetic and epigenetic aspects

Beckwith-Wiedemann syndrome is a disorder with complex genetic and epigenetic alterations that occur in the chromosomal region 11p15.5. Genomic imprinting is a phenomenon that causes genes to be expressed according to their parental origin. Approximately 40 imprinted genes have now been identified in the human genome, with roles in prenatal growth, development of particular cell lineages, and in human diseases.19 The imprinting mechanism is still unclear, but probably involves differential methylation of specific sites in or near imprinted genes. It is characterized by a methylation pattern specific for the parental allele. Uniparental disomy is another phenomenon that involves and displays imprinting effects. It occurs when a pair of homologous chromosomes is inherited from the same parent. There are several mechanisms that could give rise to uniparental disomy, but the most common is “trisomic rescue”, involving the loss of a supernumerary chromosome from a trisomic conceptus, leaving two homologues from the same gamete.20

The chromosomal region 11p15.5 is divided into two imprinted gene clusters: IGF2 and H19 are mapped in the telomeric domain; and CDKN1C (also know as p57kip2), KVLQT1 and LIT1 (also know as KvLQT 1AS) in the centromeric domain (Figure 2) (Table 1).21-32 Genes IGF2 and H19 are coordinately regulated in normal tissues through an expression competition model.33,34 On the expressed maternal H19 allele, the differential methylated region (H19DMR), mapped 2 kb upstream from this gene, is nonmethylated and is able to bind to an insulator protein CCCTC-binding factor termed CTCF. This insulates the maternal IGF2 promoter from enhancers located 3’ from the H19 gene, and prevents expression of IGF2. On the paternal allele, the H19DMR is methylated. This blocks the binding of the CTCF protein and prevents expression of the imprinted paternal H19 alleles.35 The IGF2 promoter now has access to the 3’ enhancers and the paternal allele is expressed via enhancers and boundary elements.36 This suggests that H 19DMR may function as a regional imprinting center that regulates the telomeric 11p15 imprinted domain. Deletion of the entire DMR results in loss of imprinting, with activation of H19 expression and reduction of IGF 2 paternal expression when paternally inherited. The IGF2 maternal allele is activated and the maternal H19 expression is reducted when the deletion is maternally inherited.37,38 In the centromeric domain, the KvDMR1, a maternally methylated CpG island at the 5’ end of the LIT1 transcript, may function as a regional imprinting center. Loss of methylation of KvDMR1 has been associated with biallelic expression of LIT1 in some Beckwith-Wiedemann syndrome cases.31

Figure 2 Telomeric and centromeric domains involved in Beckwith-Wiedemann syndrome. Expressed genes are indicated by open boxes, and silenced genes by closed ones. The arrows indicate the transcriptional orientation.

Table 1 Candidate genes in Beckwith-Wiedemann syndrome and in isolated hemihyperplasia

Gene	Map	Expression	Product	Characteristics	
IGF2	11p15.5 - tel	pat	Insulin-like growth factor II	Hyperexpression in 50% of sporadic cases of Beckwith-Wiedemann syndrome24,25,26 and in several tumors.27,28	
H19	11p15.5 - tel	mat	Nontranslated mRNA	Tumor suppressor gene.29
Harbors an IC region.37	
CDKN1C	11p15.5-cent	mat	Cyclin-dependent kinase inhibitor	Cell cycle regulator.30	
KvLQT1	11p15.5-cent	mat	Potassium channel	Harbors an IC region.24	
LIT1	11p15.5-cent	pat	Antisense transcript	Lies within the KvlQT1 gene.31,32	
Note: IC = imprinting control; tel = telomeric; cent = centromeric; pat = paternal; mat = maternal.

Etiology of Beckwith-Wiedemann syndrome and isolated hemihyperplasia

The etiology of Beckwith-Wiedemann syndrome is complex and genetic and/or epi-genetic alterations have been described. In approximately 15% of patients, Beckwith-Wiedemann syndrome is inherited as an autosomal dominant pattern with variable expressivity and incomplete penetrance; 2% of patients have cytogenetics abnormalities and the remainder are sporadic. Imprinted genes have been implicated in the pathogenesis of both familial and sporadic Beckwith-Wiedemann syndrome (Table 2).39-47 Isolated hemihyperplasia and other mild manifestations of Beckwith-Wiedemann syndrome may represent patchy overexpression of the IGF2 gene following defective imprinting.17 The frequency of hemihyperplasia among Beckwith-Wiedemann syndrome patients with unipa-rental disomy or aberrant methylation of both H 19 and LIT1 has been found to be significantly higher than that in patients without such defects.48 Defects in imprinting are also related to the development of a number of cancers, including Wilms’ tumor, neuroblastoma, acute myeloblastic leukemia, and rhabdomyosarcoma.49,50 Many authors have hypothesized that there may be a relationship between cancer risk and loss of imprinting of IGF 2 and/or aberrant methylation of the H 19DMR, because both defects have been described in cancers detected in children with Beckwith-Wiedemann syndrome, especially Wilms ’ tumor.39,51-53 Imprinting defects in the centromeric domain (KvDMR) of Beckwith-Wiedemann syndrome patients have been observed in rhabdomyosarcoma, hepatoblastoma and gonadoblastoma, but not in Wilms’ tumor. This suggests that distinct tumor predisposition profiles result from deregulation of the telomeric domain versus the centromeric domain and that these imprinting defects activate distinct genetic pathways for embryonic tumorigenesis.13

Table 2 Mechanisms involved in Beckwith-Wiedemann syndrome (alterations and results)

Alteration	Results	
Abnormal methylation of H19DMR.39,40	Allows access by the IGF2 maternal allele to the enhancer.41,42	
Loss of imprinting of IGF2	Activation of the IGF2 maternal allele.25,28,31
Hyperexpression of IGF2 in mice results in the spectrum of the Beckwith-Wiedemann syndrome phenotype.43	
Chromosomal rearrangements	Disruption of imprinted gene expression.44	
CDKN1C mutations	Present in familial cases of Beckwith-Wiedemann syndrome.45,46	
Loss of imprinting of LIT1	Linked to abnormal methylation of KvDMR.31	
Uniparental disomy of 11p15	Gene hyperexpression by activation of a normally silenced allele.47	
Note: DMR = differential methylated region.

METHOD

After analyzing the papers in the literature, we created an experimental protocol for the identification of Beckwith-Wiedemann syndrome and isolated hemihyperplasia, and to elucidate the mechanisms involved in the condition. This protocol has been used at the Department of Genetics of the Faculdade de Medicina de Ribeirão Preto, Universidade de S ão Paulo, and for the management of the patients and genetic family counseling in the Genetic Outpatient Service of the Hospital Universit ário of the Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.

PATIENTS

For those families who have agreed to participate in the protocol, an informed consent and medical-information release document has been obtained, as approved by the respective institutional review boards. For the purpose of such studies, we define patients as having Beckwith-Wiedemann syndrome if a clinical diagnosis has been made by a physician. The following specific criteria also need to be fulfilled: presence of 3 major findings (macroglossia, pre or postnatal growth > 90th percentile, and abdominal wall defects) or 2 major features plus 3 or more minor features such as ear signs (ear lobe creases or posterior helical ear pits), facial nevus flammeus, hypoglycemia, nephromegaly and hemihyperplasia .6,56,55 Patients with isolated hemihyperplasia or asymmetric overgrowth have also been analyzed, because they share a predisposition with Beckwith-Wiedemann syndrome patients for the same neoplasia, especially Wilms’ tumor. The mechanism involved in isolated hemihyperplasia may have links with the mechanism for Beckwith-Wiedemann syndrome.

CLINICAL MANAGEMENT

Prenatal ultrasound has occasionally been helpful when certain characteristics (omphalocele, enlarged abdominal circumference, enlarged kidneys, protruding tongue) are present. Monitoring the glycemia in Beckwith-Wiedemann syndrome newborns every 6 hours during the first 3 days, in order to correct blood glucose levels, can prevent complications in the central nervous system.10 Everman et al (2000)56 conducted a study of serial alpha-fetoprotein concentration in 22 Beckwith-Wiedemann patients. The concentration was greater in Beckwith-Wiedemann syndrome patients and declined during the postnatal period at a significantly slower rate than in healthy children. Tongue correction surgery may be necessary in some severe cases. Follow-up by ultrasound is warranted in all patients with Beckwith-Wiedemann syndrome, especially in cases associated with hemihyperplasia and/or nephromegaly, and in patients with isolated hemihyperplasia due to predisposition to embryonic tumors, including Wilms’ tumor. The screened patients should be submitted to at least 2 ultrasounds per year up to the age of 5-7 years, and then annually until puberty. Some screening sonogram programs use intervals of 4 months or less.57-59

Cytogenetic analysis

Conventional cytogenetic analysis of peripheral blood lymphocytes is performed60 and the slides are subjected to standard Giemsa staining .61 High resolution banding and in-situ fluorescence hybridization may be used in specific cases. The karyotype description should follow the nomenclature recommended by the International System for Human Cytogenetic Nomenclature (1995).

Molecular analysis

Genomic DNA is isolated from peripheral-blood lymphocytes. In the analysis of uniparental disomy, patient, paternal and maternal samples are genotyped by ApaI/IGF2 and RsaI/H19 restriction fragment length polymorphism. Non-informative cases are genotyped with at least two microsatellite markers. IGF2 gene expression analysis (skin fibroblast RNA extraction) allows the detection of loss of imprinting. This is a highly invasive methodology that requires biopsy. For this reason we use it only in specific cases. As an alternative to this, we can use less invasive methodology based on the relationship between IGF2 and H19 correlated expression. Digestion using methylation-sensitive and nonsensitive enzymes and bisulfite DNA treatment allows the analysis of H19DMR and KvDMR methylation, and gene sequencing allows the analysis of CDKN1C mutations (Figure 3).

Figure 3 Protocol for Beckwith-Wiedemann syndrome analysis.

DISCUSSION/CONCLUSION

Beckwith-Wiedemann syndrome is an overgrowth syndrome with tumor predisposition in childhood. It can be inherited but most cases are sporadic. The etiology is not totally clear, but some genetic and epi-genetic aspects may be involved, like chromosomal rearrangements in the 11p15.5 region (2%), mutations and imprinting defects of genes, most probably involving methylation of the differential methylated region and uniparental disomy. Isolated hemihyperplasia is of unknown cause, and it may represent a partial or incomplete expression of Beckwith-Wiedemann syndrome. The heterogeneous genetic and epi-genetic basis of Beckwith-Wiedemann syndrome and isolated hemihyperplasia hampers understanding of the mechanisms involved in these disorders. Knowledge of the clinical and molecular basis of Beckwith-Wiedemann syndrome and isolated hemihyperplasia, establishment of a relationship between the causes of Beckwith-Wiedemann syndrome and etiology of isolated hemihyperplasia, with an experimental protocol for their study, may be useful for patient management and better genetic counseling of their families.

Marcus Vinícius de Matos Gomes. MSc student, Department of Genetics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.

Ester Silveira Ramos, MD, PhD. Department of Genetics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil and Department of Obstetrics and Gynecology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.

Sources of funding: CNPq (grant no. 130650/2002-1), FAPESP (grant no. 1998/16573-8) and PRONEX (grant no. 661036/1998-7)

Department of Genetics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
==== Refs
REFERENCES

1 Wiedemann HR Complexe malformatif familial avec hernie ombilicale et macroglossie - un ‘syndrome nouveau’? J Genet Hum 1964 13 223 232 14231762
2 Beckwith JB Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly Birth Defects Orig Art Ser 1969 2 188 196
3 Li M Squire JA Weksberg R Overgrowth syndromes and genomic imprinting: from mouse to man Clin Genet 1998 53 3 165 170 9630066
4 Mannens M Alders M Redeker B Positional cloning of genes involved in the Beckwith-Wiedemann syndrome, hemihypertrophy, and associated childhood tumors Med Pediatr Oncol 1996 27 5 490 494 8827079
5 Elliot M Bayly R Cole T Temple IK Maher ER Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases Clin Genet 1994 46 2 168 174 7820926
6 Martínez y Martínez R Clinical features in the WiedemannBeckwith syndrome Clin Genet 1996 50 4 272 274 9001817
7 Sippell WG Partsch CJ Wiedemann HR Growth, bone maturation and pubertal development in children with the EMG-syndrome Clin Genet 1989 35 1 20 28 2924431
8 Irving IM Exomphalos with macroglossia: a study of eleven cases J Pediat Surg 1967 2 6 499 507 4865835
9 Wiedemann HR Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome Euro J Pediat 1983 141 129 129
10 Martínez y Martínez R Martínez-Carboney R OcampoCampos R Wiedemann-Beckwith syndrome: clinical, cytogenetical and radiological observations in 39 new cases Genet Couns 1992 3 2 67 76 1642813
11 Sotelo-Avila C Gonzalez-Crussi F Fowler JW Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential J Pediat 1980 96 1 47 50 7350313
12 Schneid H Vazquez MP Vacher C Gourmelen M Cabrol S Le Bouc Y The Beckwith-Wiedemann syndrome phenotype and the risk of cancer Med Pediat Oncol 1997 28 6 411 415
13 Weksberg R Nishikawa J Caluseriu O Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1 Hum Mol Genet 2001 10 26 2989 3000 11751681
14 Cohen MM A comprehensive and critical assessment of overgrowth and overgrowth syndromes Adv Hum Genet 1989 18 181 303 373-6 2658495
15 Rowe NH Hemifacial hypertrophy: review of the literature and addition of four cases Oral Surg 1962 15 572 576 14494649
16 Tomooka Y Onitsuka H Goya T Congenital hemihypertrophy with adrenal adenoma and medullary sponge kidney Br J Radiol 1988 61 729 851 853 3052686
17 Hoyme HE Seaver LH Jones KL Isolated hemihyperplasia (hemihypertrophy): Report of a prospective multicenter study of the incidence of neoplasia and review Am J Med Genet 1998 79 4 274 278 9781907
18 Leisenring WM Breslow NE Evans IE Increased birth weights of National Wilms’ Tumor Study patients suggest a growth factor excess Cancer Res 1994 54 17 4680 4683 8062264
19 Reik W Davies K Dean W Kelsey G Constância M Imprinted genes and the coordination of fetal and postnatal growth in mammals Novartis Found Symp 2001 237 19 31 discussion 31-42 11444044
20 Engel E DeLozier-Blanchet CD Uniparental disomy, isodisomy, and imprinting: probable effects in man and strategies for their detection Am J Med Genet 1991 40 4 432 439 1746607
21 Reik W Maher ER Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome Trends Genet 1997 13 8 330 334 9260520
22 Maher ER Reik W Beckwith-Wiedemann syndrome: imprinting in cluster revisited J Clin Invest 2000 105 3 247 252 10675349
23 Engel JR Smallwood A Harper A Epigenotype-pheno-type correlations in Beckwith-Wiedemann syndrome J Med Genet 2000 37 12 921 926 11106355
24 Brown KW Villar AJ Bickmore W Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway Hum Mol Genet 1996 5 12 2027 2032 8968759
25 Weksberg R Teshima I Williams BR Molecular characterization of cytogenetic alterations associated with the Beckwith-Wiedemann syndrome (BWS) phenotype refines the localization and suggests the gene for BWS is imprinted Hum Mol Genet 1993 2 5 549 556 8518793
26 Li M Squire JA Weksberg R Molecular genetics of WiedemannBeckwith syndrome Am J Med Genet 1998 79 4 253 259 9781904
27 Hashimoto K Azuma C Koyama M Loss of imprinting in choriocarcinoma Nat Genet 1995 9 2 109 110 7719334
28 Ogawa O Becroft DM Morison IM Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms’ tumour and gigantism Nat Genet 1993 5 4 408 412 8298652
29 Hao Y Crenshaw T Moulton T Newcomb E Tycko B Tumour suppressor activity of H19 RNA Nature 1993 365 6448 764 767 7692308
30 Matsuoka S Edwards MC Bai C p57 KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene Genes Dev 1995 9 6 650 662 7729684
31 Lee MP DeBaun MR Mitsuya K Loss of imprinting of a paternally expressed transcript, with antisense orientation to KvLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin like growth factor II imprinting Proc Natl Acad Sci USA 1999 96 9 5203 5208 10220444
32 Smilinich NJ Day CD Fitzpatrick GV A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome Proc Natl Acad Sci USA 1999 96 14 8064 8069 10393948
33 Barlow DP Competition - a common motif for the imprinting mechanism? EMBO J 1997 16 23 6899 6905 9384569
34 Webber AL Ingram RS Levorse JM Tilghman SM Location of enhancers is essential for the imprinting of H19 and Igf2 genes Nature 1998 391 6668 711 715 9490417
35 Hark AT Schoenherr CJ Katz DJ Ingram RS Levorse JM Tilghman SM CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus Nature 2000 405 6785 486 489 10839547
36 Kanduri C Pant V Loukinov D Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive Curr Biol 2000 10 14 853 856 10899010
37 Thorvaldsen JL Duran KL Bartolomei MS Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2 Genes Dev 1998 12 23 3693 3702 9851976
38 Srivastava M Hsieh S Grinberg A Williams-Simons L Huang SP Pfeifer K H19 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19 Genes Dev 2000 14 10 1186 1195 10817754
39 Steenman MJ Rainier S Dobry CJ Grundy P Horon IL Feinberg AP Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms’ tumour Nat Genet 1994 7 3 433 439 7920665
40 Reik W Brown KW Schneid H Le Bouc Y Bickmore W Maher ER Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain Hum Mol Genet 1995 4 12 2379 2385 8634713
41 Feinberg AP Cancer epigenetics takes center stage Proc Natl Acad Sci USA 2001 98 2 392 394 11209042
42 Bell AC Felsenfeld G Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene Nature 2000 405 6785 482 485 10839546
43 Sun FL Dean WL Kelsey G Allen NA Reik W Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome Nature 1997 389 6653 809 815 9349812
44 Lee MP Hu RJ Johnson LA Feinberg AP Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements Nat Genet 1997 15 2 181 185 9020845
45 Lee MP DeBaun M Randhawa G Low frequency of p57 KIP2 mutation in Beckwith-Wiedemann Am J Hum Genet 1997 61 2 304 309 9311734
46 Lam WW Hatada I Ohishi S Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel geno-type-phenotype correlation J Med Genet 1999 36 7 518 523 10424811
47 Henry I Bonaiti-Pellié C Chehensse V Uniparental paternal disomy in a genetic cancer-predisposing syndrome Nature 1991 351 6328 665 667 1675767
48 DeBaun MR Niemitz EL McNeil DE Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects Am J Hum Genet 2002 70 3 604 611 11813134
49 Falls JG Pulford DJ Wylie AA Jirtle RL Genomic imprinting: implications for human disease Am J Pathol 1999 154 3 635 647 10079240
50 Moulton T Chung WY Yuan L Genomic imprinting and Wilms’ tumor Med Pediatr Oncol 1996 27 5 476 483 8827077
51 Ogawa O Eccles MR Szeto J Relaxation of insulin-like growth factor II gene imprinting in Wilms’ tumour Nature 1993 362 6422 749 751 8097018
52 Rainier S Johnson LA Dobry CJ Ping AJ Grundy PE Feinberg AP Relaxation of imprinted genes in human cancer Nature 1993 362 6422 747 749 8385745
53 Tycko B Epigenetic gene silencing in cancer J Clin Invest 2000 105 4 401 407 10683367
54 Elliott M Bayly R Cole T Temple IK Maher ER Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases Clin Genet 1994 46 2 168 174 7820926
55 DeBaun MR Tucker MA Risk of cancer during the first four years of life in children form The Beckwith-Wiedemann Syndrome Registry J Pediatr 1998 132 3 Pt 1 398 400 9544889
56 Everman DB Shuman C Dzolganovski B O'riordan MA Weksberg R Robin NH Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome J Pediatr 2000 137 1 123 127 10891834
57 Borer JG Kaefer M Barnewolt CE Renal findings on radiological followup of patients with Beckwith-Wiedemann syndrome J Urol 1999 16 1 235 239
58 Choyke PL Siegel MJ Craft AW Green DM DeBaun MR Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy Med Pediatr Oncol 1999 32 3 196 200 10064187
59 McNeil DE Brown M Ching A DeBaun MR Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model Med Pediatr Oncol 2001 37 4 349 356 11568898
60 Moorhead PS Norwell PC Meliman WJ Battips DM Hungerford DA Chromosome preparations of leukocyte cultures from human peripheral blood Exp Cell Res 1960 20 654 656
61 Scheres JM Human chromosome banding Lancet 1972 1 7755 849 849
